Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Recruiting now

Conditions studied: Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis

In brief

The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.

Key facts

Study ID

NCT07265544

Run by

Nanfang Hospital, Southern Medical University

People needed

240

Starts

2023-03-01

Expected to finish

2027-02-12

Last updated by the study team

2026-04-14

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Voluntarily signed the informed consent form;
• No restrictions on age and gender;
• Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)";
• Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.

You may not qualify if…

• Individuals with concurrent infections such as HIV will be excluded.
• Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.
• Those with severe underlying diseases that affect the body's immune status will be excluded.
• Individuals whom the investigator deems unsuitable for participation in this study will be excluded.

Where it is running

• Nan — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.